Articles

Nivolumab continues to be an effective adjuvant treatment for patients with resected high-risk melanoma at 4 years, with sustained recurrence-free and distant metastasis-free survival benefit compared with ipilimumab. Read More ›

Analysis of the randomized COMBI-AD trial at 5 years shows >50% relapse-free survival in patients with resected stage III BRAF V⁶⁰⁰-mutation–positive melanoma who received adjuvant treatment with the combination of dabrafenib plus trametinib. Read More ›

The latest analysis of the phase 3 EORTC 1325/KEYNOTE-054 clinical trial showed pembrolizumab to be superior to placebo after more than 3.5 years of follow-up on the end points of distant metastasis-free survival and relapse-free survival in patients with resected stage III melanoma. Read More ›

Thyroid cancer is the most common form of endocrine malignancy and its incidence is increasing. Thyroid cancers usually present as painless nodules found upon palpation, and nodules >1 cm should be evaluated as they have a higher potential for being clinically significant cancers. Read More ›

RET is a tyrosine kinase receptor that, when fused with a partner molecule, activates oncogenic activity. RET abnormalities are found in both papillary and medullary thyroid cancers and are promising targets for treatment. Read More ›

Medullary thyroid cancer (MTC) accounts for 5% of all thyroid cancers. The only curative treatment option for MTC is surgery, but understanding of the RET pathway and the development of therapies targeting this pathway may improve outcomes for these patients. Read More ›

Papillary thyroid cancer is the most prevalent thyroid cancer, accounting for 80% of thyroid cancer diagnoses. Prognosis is good for patients with early and aggressive treatment, and the new and emerging therapies targeting the RET pathway may improve outcomes for patients with advanced disease. Read More ›

Among patients with radioiodine-refractory advanced or metastatic thyroid cancer, tyrosine kinase inhibitors are guideline recommended. New RET-specific kinase inhibitors have recently demonstrated positive outcomes for these patients. Read More ›

In response to the COVID-19 pandemic, CMS has added coverage of telehealth services as part of a push by the agency to accelerate the use of telehealth by removing reimbursement barriers. Read More ›

The international phase 3 INOVATYON clinical trial did not meet its primary end point of an improvement in overall survival with trabectedin added to pegylated liposomal doxorubicin (PLD) followed by platinum at progression compared with carboplatin plus PLD in patients with recurrent ovarian cancer. Trabectedin plus PLD may still have a role in patients with multiple previous lines of platinum. Read More ›